Desenvolvimento de Vacinas: o potencial do Instituto Butantan na Pandemia de Covid-19

Gabriela Simões  Pazelli; Ana Marisa Chudzinski-Tavassi; Alexandre Guimaraes Vasconcellos

doi:10.9771/cp.v15i4.48379

Authors

Gabriela Simões Pazelli Butantan Institute, São Paulo, SP, Brazil https://orcid.org/0000-0003-1814-3678
Ana Marisa Chudzinski-Tavassi Butantan Institute, São Paulo, SP, Brazil https://orcid.org/0000-0001-7717-7013
Alexandre Guimaraes Vasconcellos National Institute of Industrial Property, Rio de Janeiro, RJ, Brazil https://orcid.org/0000-0003-4791-6932

DOI:

https://doi.org/10.9771/cp.v15i4.48379

Keywords:

COVID-19, Technology transfer, Vaccines.

Abstract

Vaccines' development and production capacity are essentials in the fight against diseases. This process becomes urgent during pandemics, such as Covid-19, with very high death numbers. This study aims to clarify how the technology transfer strategy applied in Brazil, applied by Instituto Butantan, benefits the vaccine development. Using documentary research, this work addresses the challenges faced in vaccine production. The structure already installed at Butantan was essential for its role in the face of Covid-19, as the adopted partnerships and the use of knowledge already acquired stand out. The use of technologies already mastered speeds up the product development process and reduces financial investment, and fully national production contributes to reversing its situation of technological vulnerability. For these initiatives to continue, a policy for investments in the health industrial complex is essential, and support for projects and personnel involved in RD&I at the institution and in Brazil.

Downloads

Download data is not yet available.

Author Biographies

Gabriela Simões Pazelli, Butantan Institute, São Paulo, SP, Brazil

Graduated in Biomedical Sciences from the Faculty of Medicine of Ribeirão Preto (FMRP/USP) with emphasis on Health Biotechnology, graduated at a technical level in Nutrition and Dietetics. She was a scholarship student for Initiation in Technological Development and Innovation (PIBITI) at the Laboratory of Hereditary Metabolic Diseases of the Genetics Department at FMRP. Co-founder and first marketing director at Sirius Biotecnologia Jr.. She was also a FAPESP scientific initiation scholarship student at the Butantan Institute's Center of Excellence for Molecular Target Discoveries (CENTD). She is currently a Master's student in the Postgraduate Program in Molecular Biology at Escola Paulista de Medicina, Federal University of São Paulo (EPM/UNIFESP), developing her project at CENTD.

Ana Marisa Chudzinski-Tavassi, Butantan Institute, São Paulo, SP, Brazil

Graduated in Pharmacy and Biochemistry from the Federal University of Paraná, UFPR. Master's and Doctorate in Sciences from the Federal University of São Paulo - UNIFESP (Molecular Biology program). Doctorate by the Pasteur Institute and INSERM (France). He held a Post-Doctorate at the National Academy of Medicine of Buenos Aires (ANMBs) - Argentina. She is a PqC-VI scientific researcher at the Butantan Institute where she works as: Director of the Development and Innovation Center of the Butantan Institute, Director of the CENTD: Center of Excellence in New Target Discovery - FAPESP/GSK/IBu. She is a Productivity Researcher at CNPq and Associate Researcher at CeTICS - FAPESP. She is an accredited professor in the Postgraduate courses: Molecular Biology at UNIFESP, Interunits in Biotechnology - at USP and Postgraduate Studies in Toxinology - at the Butantan Institute. He is a member of the Municipal Council of Science and Technology and Innovation of the City of São Paulo and is a member of the Brazilian Network of Pharmaceutical Innovation. She works as an Ad Hoc reviewer for several scientific journals and Funding Agencies. It coordinates projects aimed at public-private interaction, with the support of various funding agencies. Experience in the field of Biochemistry, with emphasis on the discovery of molecules that act in immunoinflammatory diseases, cell survival, hemostasis and tissue remodeling. Coordinates projects for discovery and validation of molecular targets in different cellular models. Coordinates projects for the implementation of infrastructure for the development of new drugs, such as laboratories with different levels of biosafety, multipurpose laboratories, specialized platforms for discovery and validation of molecular targets and biorepositories. It provides training in entrepreneurship and innovation through free courses and courses in undergraduate and graduate programs

Alexandre Guimaraes Vasconcellos, National Institute of Industrial Property, Rio de Janeiro, RJ, Brazil

Graduated in Full Degree in Biological Sciences from the Federal University of Rio de Janeiro (1995), MBA in Public Policy Management (Innovation and Intellectual Property) from the Institute of Economics of UFRJ (2006), Master's in Biological Sciences (Biophysics) from the Universidade Federal University of Rio de Janeiro (1998), PhD in Plant Biotechnology from the Federal University of Rio de Janeiro (2003) and Senior Post-Doctorate on Innovation Management in Neglected Diseases at the FIOCRUZ Health Technology Development Center (2011) and at the Global Challenges Division of the World Intellectual Property Organization, Geneva-Switzerland (2016). He has been a Researcher in Industrial Property at INPI since 1998, having been promoted to the Special Class in 2009. He works in the Postgraduate and Research Division (DIPGP), being Permanent Professor at the INPI Intellectual Property and Innovation Academy since its creation in 2006. He shares the leadership of the Research Group on Intellectual Property in Biotechnology and Health (PIBIOS) at the institution. He has been an External Advisor and Collaborating Professor of the Postgraduate Program in Marine Biotechnology at the IEAPM since 2016. He has experience and is involved with teaching activities, mentoring master's and doctoral students and research in the areas of Intellectual Property in the Biotechnology and Pharmaceuticals sectors. , Technological Innovation, Technological Information and Traditional Knowledge and Associated Rights, having already given more than 100 presentations in Brazil and abroad on these subjects.

References

AHN, Dae-Gyun et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol., [s.l.], v. 30, n. 3, p. 313-324, 21 mar. 2020. DOI https://doi.org/10.4014/jmb.2003.03011. Disponível em: https://www.jmb.or.kr/journal/view.html?uid=5371&vmd=Full. Acesso em: 15 abr. 2022.

ANVISA – AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Anvisa autoriza pesquisa clínica da vacina Butanvac. Ministério da Saúde, 10 jun. 2021a. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-autoriza-pesquisa-clinica-da-vacina-butanvac. Acesso em: 15 abr. 2022.

ANVISA – AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Covid-19: fique por dentro do mapa das vacinas em teste no Brasil. 17 jun. 2021b. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2020/fique-por-dentro-do-mapa-das-vacinas-em-teste-no-brasil. Acesso em: 15 abr. 2022.

ANVISA – AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Estudos clínicos com vacinas. 2022a. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/vacinas/estudos-clinicos. Acesso em 23 ago. 2022.

ANVISA – AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Vacinas – Covid-19. 24 ago. 2022b. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/vacinas. Acesso em: 23 ago. 2022.

AWAD, E. A Primeira Vacina 100% Brasileira! Entrevista Dra. Ana Marisa Tavassi. YouTube, 2021a. Disponível em: https://www.youtube.com/watch?v=CuPqFN5K-9Q. Acesso em: 15 abr. 2022.

AWAD, E. Atualização sobre as Vacinas: Estudos, Cenários E Perspectivas!! YouTube, 2021b. Disponível em: https://www.youtube.com/watch?v=KzF4ivMyqhU. Acesso em: 15 abr. 2022.

AWAD, E. Insumos para Produção de Vacinas, Indústria Farmacêutica, Entrevista com Silvia Sfeir. YouTube, 2021c. Disponível em: https://www.youtube.com/watch?v=yM1SB12uALs. Acesso em: 15 abr. 2022.

BERTONI, E. O impacto da suspensão da produção de vacinas no Brasil. Nexo, 18 maio 2021. Disponível em: https://www.nexojornal.com.br/expresso/2021/05/17/O-impacto-da-suspensão-da-produção-de-vacinas-no-Brasil. Acesso em: 15 abr. 2022.

CANAL BUTANTAN. 20 Anos de Parceria Instituto Butantan – Sanofi Pasteur. Direção: Valesca Canabarro Dios. Produção: Rafael Simões. Roteiro: Valesca Canabarro Dios. YouTube, 2019. Disponível em: https://www.youtube.com/watch?v=xy5l8r2KzHw. Acesso em: 15 abr. 2022.

CHAMAS, C. Inovação, propriedade intelectual e acesso a medicamentos e vacinas: o debate internacional na pandemia da Covid-19. Liinc em Revista, [s.l.], v. 16, n. 2, p. e5338, 2020. DOI: 10.18617/liinc.v16i2.5338. Disponível em: http://revista.ibict.br/liinc/article/view/5338. Acesso em: 15 abr. 2022.

DE FRANCO, M.; KALIL, J. The Butantan Institute: History and Future Perspectives. PLOS: Neglected Tropical Diseases, [s.l.], 3 jul. 2014. DOI https://doi.org/10.1371/journal.pntd.0002862. Disponível em: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002862. Acesso em: 15 abr. 2022.

EL PAÍS BRASIL. El País TV entrevista Ricardo Palacios. YouTube, 2020. Disponível em: https://www.youtube.com/watch?v=NbVDT2dVZak. Acesso em: 15 abr. 2022.

GAO, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science, [s.l.], v. 369, n. 3, ed. 6.499, p. 77-81, 6 jun. 2020. DOI https://doi.org/10.1126/science.abc1932. Disponível em: https://www.science.org/doi/full/10.1126/science.abc1932. Acesso em: 15 abr. 2022.

HO, P. L. et al. Economical Value of Vaccines for the Developing Countries: The Case of Instituto Butantan, a Public Institution in Brazil. PLOS: Neglected Tropical Diseases, [s.l.], v. 5, 29 nov. 2011. DOI https://doi.org/10.1371/journal.pntd.0001300. Disponível em: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001300. Acesso em: 15 abr. 2022.

HOMMA, A.; FREIRE, M. S.; POSSAS, C. Vacinas para doenças negligenciadas e emergentes no Brasil até 2030: o “vale da morte” e oportunidades para PD&I na Vacinologia 4.0. Cadernos de Saúde Pública, [s.l.], v. 36, 2020. DOI https://doi.org/10.1590/0102-311X00128819. Disponível em: https://www.scielo.br/j/csp/a/7Hxhd5TBN89TzYYxqmbnxvz/?lang=pt&format=html. Acesso em: 15 abr. 2022.

INPI – INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL. Observatório COVID-19: Observatório de Tecnologias Relacionadas à COVID-19. 8 abr. 2022. Disponível em: https://www.gov.br/inpi/pt-br/servicos/patentes/tecnologias-para-covid-19. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. Butantan e Governo de SP vão testar e produzir vacina inédita contra coronavírus. Instituto Butantan, 11 jun. 2020a. Disponível em: https://butantan.gov.br/noticias/butantan-e-governo-de-sp-vao-testar-e-produzir-vacina-inedita-contra-coronavirus. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. Governo de SP inicia as obras da fábrica que produzirá Coronavac no Brasil. Instituto Butantan, 9 nov. 2020b. Disponível em: https://butantan.gov.br/noticias/governo-de-sp-inicia-as-obras-da-fabrica-que-produzira-coronavac-no-brasil. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. SP inicia produção brasileira de vacina do Butantan. Instituto Butantan, 18 dez. 2020c. Disponível em: https://butantan.gov.br/noticias/sp-inicia-producao-brasileira-de-vacina-do-butantan. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. A parceria tecnológica que fez da CoronaVac a vacina do Brasil. Instituto Butantan, 18 jan. 2021a. Disponível em: https://butantan.gov.br/noticias/a-parceria-tecnologica-que-fez-da-coronavac-a-vacina-do-brasil. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. Butantan entrega 6,9 milhões de doses da CoronaVac, encerra contrato de 100 milhões de doses com Ministério e inicia substituição de vacinas retidas. Instituto Butantan, 15 set. 2021b. Disponível em: https://butantan.gov.br/noticias/butantan-entrega-69-milhoes-de-doses-da-coronavac-encerra-contrato-de-100-milhoes-de-doses-com-ministerio-e-inicia-substituicao-de-vacinas-retidas. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. Butanvac deve ter melhor resposta contra variantes e será produzida no país: entenda a tecnologia. Instituto Butantan, 17 ago. 2021c. Disponível em: https://butantan.gov.br/noticias/butanvac-deve-ter-melhor-resposta-contra-variantes-e-sera-produzida-no-pais--entenda-a-tecnologia. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. ButanVac não vai impactar acordo do Butantan para produção da CoronaVac, garante Dimas Covas. Instituto Butantan, 9 abr. 2021d. Disponível em: https://butantan.gov.br/noticias/butanvac-nao-vai-impactar-acordo-do-butantan-para-producao-da-coronavac-garante-dimas-covas. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. ButanVac será barata e é resultado do acúmulo de experiências do Butantan com produção da CoronaVac. Instituto Butantan, 29 mar. 2021e. Disponível em: https://butantan.gov.br/noticias/butanvac-sera-barata-e-e-resultado-do-acumulo-de-experiencias-do-butantan-com-producao-da-coronavac. Acesso em: 15 abr. 2022.

INSTITUTO BUTANTAN. Vacinas. 2022. Disponível em: https://butantan.gov.br/soros-e-vacinas/vacinas. Acesso em: 15 abr. 2022.

JARED, C. O surto da peste em Santos, o Butantan e a COVID-19. Canal Butantan, 17 jun. 2020. Disponível em: https://coronavirus.butantan.gov.br/ultimas-noticias/o-surto-da-peste-em-santos-o-butantan-e-a-covid-19. Acesso em: 15 abr. 2022.

JESUS, C. S. et al. The role of the National Health Surveillance Agency in the regulation of vaccines. Research, Society and Development, [s.l.], v. 10, n. 6, p. e35010614512, 2022. DOI: 10.33448/rsd-v10i6.14512. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/14512. Acesso em: 15 abr. 2022.

LUNDQUIST, G. A Rich Vision of Technology Transfer Technology Value Management. The Journal of Technology Transfer, [s.l.], v. 28, p. 265-284, 2003. DOI https://doi.org/10.1023/A:1024949029313. Disponível em: https://link.springer.com/article/10.1023/A:1024949029313#citeas. Acesso em: 15 abr. 2022.

LURIE, N. et al. Developing Covid-19 Vaccines at Pandemic Speed. The New England Journal of Medicine, [s.l.], v. 382, p. 1.969-1.973, 21 maio 2020. DOI 10.1056/NEJMp2005630. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMp2005630. Acesso em: 15 abr. 2022.

MANU, C.; VISHAL GUPTA, N. Review on Technology Transfer in Pharmaceutical Industry. International Journal of Pharmaceutical Quality Assurance, [s.l.], v. 7, p. 7-14, 1 jan. 2016. Disponível em: http://impactfactor.org/PDF/IJPQA/7/IJPQA,Vol7,Issue1,Article2.pdf. Acesso em: 15 abr. 2022.

MAZZUCATO, M. O Estado Empreendedor: desmascarando o mito do setor público vs. setor privado. São Paulo: Editora Schwarcz S.A., 2014.

MCTI – MINISTÉRIO DA CIÊNCIA, TECNOLOGIA, INOVAÇÕES E COMUNICAÇÕES DO BRASIL. Rede Vírus: sobre Rede Vírus. 2020. Disponível em: http://redevirus.mcti.gov.br/sobre/. Acesso em: 15 abr. 2022.

MIYAKI, C. et al. Influenza vaccine production for Brazil: a classic example of successful North–South bilateral technology transfer. Vaccines, [s.l.], v. 29, p. A12-A15, 1 jul. 2011. DOI https://doi.org/10.1016/j.vaccine.2011.04.127. Disponível em: https://www.sciencedirect.com/science/article/pii/S0264410X11006931. Acesso em: 15 abr. 2022.

MOHITE, P. B.; SANGLE, S. V. Technology transfer in pharmaceutical industry- A Review. International Journal of Advances in Pharmaceutics, [s.l.], v. 6, p. 1-07, 2017. DOI https://dx.doi.org/10.7439/ijap. Disponível em: https://core.ac.uk/download/pdf/335078031.pdf. Acesso em: 15 abr. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. WHO Director-General's opening remarks at the media briefing on COVID-19. 11 mar. 2020. Disponível em: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Acesso em: 15 abr. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. Timeline: WHO's COVID-19 response. 25 jan. 2021. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline. Acesso em: 15 abr. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. Draft landscape and tracker of COVID-19 candidate vaccines. 25 fev. 2022a. Disponível em: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acesso em: 23 ago. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. Vaccines: Prequalified vaccines. 2022b. Disponível em: https://extranet.who.int/pqweb/vaccines/prequalified-vaccines?sort_order=field_vaccines_effective_date&desc=ASC&page=25. Acesso em: 15 abr. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. WHO Coronavirus (COVID-19) Dashboard. 25 fev. 2022c. Disponível em: https://covid19.who.int. Acesso em: 23 ago. 2022.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. WHO Coronavirus (COVID-19) Dashboard: Brazil. 25 fev. 2022d. Disponível em: https://covid19.who.int/region/amro/country/br. Acesso em: 23 ago. 2022.

PAIVA, L. Você no Butantan: Tiago Rocca, gerente de Parcerias Estratégicas e Novos Negócios. Instituto Butantan, 14 out. 2019. Disponível em: https://www.butantan.gov.br/noticias/voce-no-butantan-tiago-rocca-gerente-de-parcerias-estrategicas-e-novos-negocios. Acesso em: 15 abr. 2022.

STÁVALE, M. C. M.; LEAL, M. L. F.; FREIRE, M. S. A evolução regulatória e os desafios na perspectiva dos laboratórios públicos produtores de vacinas no Brasil. Cadernos de Saúde Pública, [on-line], 21 set. 2020, v. 36, n. Suppl 2, e00202219. Epub. ISSN 1678-4464. Disponível em: https://doi.org/10.1590/0102-311X00202219. Acesso em: 15 abr. 2022.

UNIVERSIDADE CORNELL; INSEAD; INPI – ORGANIZAÇÃO MUNDIAL DA PROPRIEDADE INTELECTUAL. Índice Global de Inovação 2020: quem financiará a inovação? 13. ed. Ithaca; Fontainebleau; Genebra: [s.n.], 2020.

Vaccine Development: the Potential of the Butantan Institute in the Covid-19 Pandemic Scenario

Authors

DOI:

Keywords:

Abstract

Downloads

Author Biographies

Gabriela Simões Pazelli, Butantan Institute, São Paulo, SP, Brazil

Ana Marisa Chudzinski-Tavassi, Butantan Institute, São Paulo, SP, Brazil

Alexandre Guimaraes Vasconcellos, National Institute of Industrial Property, Rio de Janeiro, RJ, Brazil

References

Downloads

Published

How to Cite

Issue

Section

License

Information

Language

Keywords